The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas

Endocrine Pathology

Volumn 24, Issue 4, 2013, Pages 191-198

  Mete, Ozgur ^a,b,c   Hayhurst, Caroline ^a,b   Alahmadi, Hussein ^a,b   Monsalves, Eric ^a   Gucer, Hasan ^a,b   Gentili, Fred ^a,b,c   Ezzat, Shereen ^a,b,c   Asa, Sylvia L ^a,b,c   Zadeh, Gelareh ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

FGFR4; Integrin; MMP 1; Non Functioning Pituitary Adenoma; Osteopontin; Silent Corticotroph Adenoma

Indexed keywords

BETA1 INTEGRIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; INTERSTITIAL COLLAGENASE; OSTEOPONTIN;

ACTH SECRETING ADENOMA; ARTICLE; BIOLOGICAL ACTIVITY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DIFFERENTIAL DIAGNOSIS; GONADOTROPH ADENOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NON FUNCTIONING GONADOTROPH ADENOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SILENT CORTICOTROPH ADENOMA; STAINING;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; CELL MOVEMENT; FIBROBLAST GROWTH FACTOR 4; HUMANS; INTEGRIN BETA CHAINS; MATRIX METALLOPROTEINASE 1; NEOPLASM INVASIVENESS; OSTEOPONTIN;

EID: 84888175651     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-013-9270-y     Document Type: Article

References (61)

1. Mete O, Asa SL Clinicopathological correlations in pituitary adenomas. Brain Pathol; 22(4): 443-453, 2012.
2. Asa SL Tumors of the pituitary gland. Fascicle 15, 4th Series. The Atlas of Tumor Pathology. Washington DC: Armed Forces Institute of Pathology, 2011.
3. Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W. Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98(3):617-638, 1980.
4. Kovacs K, Horvath E, Bayley TA, Hassaram ST, Ezrin C. Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy. A distinct clinicopathologic entity. Am J Med 64(3):492-499, 1978.
5. Alahmadi H, Lee D, Wilson JR, Hayhurst C, Mete O, Gentili F, Asa SL, Zadeh G Clinical features of silent corticotroph adenomas. Acta Neurochir (Wien) 154(8):1493-1498, 2012.
6. Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61(3):580-584, 2007.
7. Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, Laws ER Jr, Young WF Jr Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery47 (3):723-729; discussion 729-730, 2000.
8. Lopez JA, Kleinschmidt-Demasters Bk Bk, Sze CI, Woodmansee WW, Lillehei KO. Silent corticotroph adenomas: further clinical and pathological observations. Hum Pathol 35(9):1137-47, 2004.
9. Bradley KJ, Wass JA, Turner HE. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol (Oxf) 58(1):59-64, 2003.
10. Cho HY, Cho SW, Kim SW, Shin CS, Park KS, Kim SY. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 72(5):648-653, 2010.
11. Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer 1(2):80-92, 2010.
12. Mete O, Ezzat S, Asa SL Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49(2): R69-78, 2012.
13. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M Ki-67 in pituitary neoplasms: a review-part I. Neurosurgery 65:429-437, 2009.
14. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M Biomarkers of pituitary neoplasms: a review (Part II) Neurosurgery 67:1790-1798, 2010.
15. Asa SL, Ezzat S The pathogenesis of pituitary tumors. Annu Rev Pathol 4:97-126, 2009.
16. Paez-Pereda M, Kuchenbauer F, Arzt E, Stalla GK Regulation of pituitary hormones and cell proliferation by components of the extracellular matrix. Braz J Med Biol Res 38:1487-1494, 2005.
17. Tougard C, Louvard D, Picart R, Tixier-Vidal A Immunocytochemical localization of laminin in rat anterior pituitary cells in vivo and in vitro. In Vitro Cellular and Developmental Biology 21: 57-61, 1985.
18. Vila-Porcile E, Picart R, Tixier-Vidal A, Tougard C Cellular and subcellular distribution of laminin in adult rat anterior pituitary. Journal of Histochemistry and Cytochemistry 35: 287-299, 1987.
19. de Carvalho DF, Silva KL, de Oliveira DA, Villa-Verde DM, Coelho HS, Silva LC, Nasciutti LE Characterization and distribution of extracellular matrix components and receptors in GH3B6 prolactin cells. Biology of the Cell 92: 351-362, 2000.
20. Horacek MJ, Thompson JC, Dada MO, Terracio L The extracellular matrix components laminin, fibronectin, and collagen IV are present among the epithelial cells forming Rathke's pouch. Acta Anatomica 147: 69-74, 1993.
21. Páez Pereda M, Ledda MF, Goldberg V, Chervín A, Carrizo G, Molina H, Müller A, Renner U, Podhajcer O, Arzt E, Stalla GK High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J Clin Endocrinol Metab 85(1):263-269, 2000.
22. Tateno T, Asa SL, Zheng L, Mayr T, Ullrich A, Ezzat S The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. PLoS Genet 7:e1002400, 2011.
23. Ezzat S, Zheng L, Asa SL Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 18:2543-1552, 2004.
24. Weber GF Invasiveness In: Weber GF. Molecular mechanisms of cancer. Springer, The Netherlands, pp. 215-282, 2007.
25. Juliano RL, Varner JA Adhesion molecules in cancer: the role of integrins. Curr Opin Cell Biol. 1993;5:812-818, 1993.
26. Akiyama SK, Nagata K, Yamada KM Cell surface receptors for extracellular matrix components. Biochim Biophys Acta 1031:91-110, 1990.
27. ffrench-Constant C, Colognato H Integrins: versatile integrators of extracellular signals. Trends Cell Biol 14:678-686, 2004.
28. Ivaska J, Heino J Adhesion receptors and cell invasion: mechanisms of integrin-guided degradation of extracellular matrix. Cell Mol Life Sci 57:16-24, 2000.
29. Milam SB, Haskin C, Zardeneta G, Chen D, Magnuson VL, Klebe RJ, Steffenson B Cell adhesion proteins in oral biology. Crit Rev Oral Biol Med 2:451-491, 1991.
30. Wang F, Shu K, Lei T, Xue D The expression of integrin-beta1 and FAK in pituitary adenomas and their correlation with invasiveness. J Huazhong Univ Sci Technolog Med Sci 28:572-575, 2008.
31. Farnoud MR, Veirana N, Derome P, Peillon F, Li JY Adenomatous transformation of the human anterior pituitary is associated with alterations in integrin expression. Int J Cancer. 67:45-53, 1996.
32. Murray K, de Lera JM, Astudillo A, McNicol AM Organisation of basement membrane components in the human adult and fetal pituitary gland and in pituitary adenomas. Virchows Arch 431:329-335, 1997.
33. Dworakowska D, Grossman AB The molecular pathogenesis of corticotroph tumours. Eur J Clin Invest 42(6):665-676, 2012.
34. Sodek J, Ganss B, McKee MD Osteopontin. Crit Rev Oral Biol Med11:279-303, 2000.
35. Murray D, Morrin M and McDonnell S Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res 24:489-94, 2004.
36. Omara-Opyene AL, Qiu J, Shah GV, Iczkowski KA Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 84:894-907, 2004.
37. Kolb A, Kleeff J, Guweidhi A, Esposito I, Giese NA, Adwan H, Giese T, Büchler MW, Berger MR, Friess H Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther 4:740-746, 2005.
38. Mi Z, Guo H, Wai PY, Gao C, Kuo PC Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 27:1134-1145, 2006.
39. Weismann D, Briese J, Niemann J, Grüneberger M, Adam P, Hahner S, Johanssen S, Liu W, Ezzat S, Saeger W, Bamberger AM, Fassnacht M, Schulte HM, Asa SL, Allolio B, Bamberger CM Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. J Pathol 218:232-240, 2009.
40. Medico E, Gentile A, Lo Celso C, Williams TA, Gambarotta G, Trusolino L, Comoglio PM Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 61:5861-5868, 2001.
41. Chackalaparampil I, Peri A, Nemir M, Mckee MD, Lin PH, Mukherjee BB, Mukherjee AB Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein. Oncogene 12:1457-1467, 1996.
42. Su L, Mukherjee AB, Mukherjee BB Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogene 10:2163-2169, 1995.
43. Qi S, Huang G, Pan J, Li J, Zhang X, Fang L, Liu B, Meng W, Zhang Y, Liu X Involvement of osteopontin as a core protein in craniopharyngioma calcification formation. J Neurooncol 98:21-30, 2010.
44. Ehrchen J, Heuer H, Sigmund R, Schäfer MK, Bauer K Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary. J Endocrinol 169:87-96, 2001.
45. Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K, Kurisu K Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochir (Wien) 138:1442-1448, 1996.
46. Hussaini IM, Trotter C, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Agi CU, Redpath GT, Fang Z, Leung GK, Lopes MB, Laws ER Jr Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol 170:356-365, 2007
47. Gong J, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Lopes MB, Hussaini IM, Laws ER Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary 11:37-48, 2008.
48. Liu W, Matsumoto Y, Okada M, Miyake K, Kunishio K, Kawai N, Tamiya T, Nagao S Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J Med Invest 52:151-158, 2005.
49. Miyoshi A, Kitajima Y, Sumi K, Sato K, Hagiwara A, Koga Y, Miyazaki K Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer 90:1265-1273, 2004.
50. Arakaki PA, Marques MR, Santos MC MMP-1 polymorphism and its relationship to pathological processes. J Biosci 34:313-320, 2009.
51. Altaş M, Bayrak OF, Ayan E, Bolukbasi F, Silav G, Coskun KK, Culha M, Sahin F, Sevli S, Elmaci IThe effect of polymorphisms in the promoter region of the MMP-1 gene on the occurrence and invasiveness of hypophyseal adenoma. Acta Neurochir (Wien) 152:1611-1617, 2010.
52. Abbass SA, Asa SL, Ezzat S Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J Clin Endocrinol Metab 82:1160-1166, 1997.
53. Zhu X, Asa SL, Ezzat S Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin Cancer Res 14:1984-1996, 2008.
54. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109:69-78, 2002.
55. Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T, Li CC, Hirokawa M, Kovacs K, Ezzat S Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab 89:1904-1911, 2004.
56. Ezzat S, Zheng L, Winer D, Asa SL Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. Mol Endocrinol 20:2965-2975, 2006.
57. Cavallaro U, Niedermeyer J, Fuxa M, Christofori G N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol 3:650-657, 2001.
58. Morita K, Takano K, Yasufuku-Takano J, Yamada S, Teramoto A, Takei M, Osamura RY, Sano T, Fujita T Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 68:435-441, 2008.
59. Sugiyama N, Varjosalo M, Meller P, Lohi J, Chan KM, Zhou Z, Alitalo K, Taipale J, Keski-Oja J, Lehti K FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. Proc Natl Acad Sci U S A 107:15786-15791, 2010.
60. Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S, Blevins L, Aghi MK A Comprehensive long-term retrospective analysis of silent corticotrophic adenomas versus hormone-negative adenomas. Neurosurgery. 2013 Mar 5. [Epub ahead of print].
61. Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 15:1113-1126, 2011.